Baseline cardiovascular risk predicts subsequent changes in resting brain function

Stroke

Volumn 43, Issue 6, 2012, Pages 1542-1547

  Beason Held, Lori L ^a   Thambisetty, Madhav ^a   Deib, Gerard ^b   Sojkova, Jitka ^a,b   Landman, Bennett A ^c   Zonderman, Alan B ^a   Ferrucci, Luigi ^a   Kraut, Michael A ^b   Resnick, Susan M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

aging; cholesterol; diabetes; hypertension; positron emission tomography

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; AGING; ANTERIOR CINGULATE; ARTICLE; BRAIN BLOOD FLOW; BRAIN STEM; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; IMAGE ANALYSIS; INSULA; MALE; MENTAL DETERIORATION; MIDDLE FRONTAL GYRUS; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPATHOLOGY; NORMAL HUMAN; ORBITAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; RESTING BRAIN FUNCTION; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE; VOXEL BASED MORPHOMETRY;

AGED; AGED, 80 AND OVER; AGING; BRAIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS;

EID: 84861607315     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.638437     Document Type: Article

References (45)

1. Waldstein SR, Wendell CR. Neurocognitive function and cardiovascular disease. J Alzheimers Dis. 2010;20:833-842.
2. de Toledo Ferraz Alves TC, Ferreira LK, Wajngarten M, Busatto GF. Cardiac disorders as risk factors for Alzheimer's disease. J Alzheimers Dis. 2010;20:749-763.
3. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag. 2008;4:363-381.
4. Musicco M, Palmer K, Salamone G, Lupo F, Perri R, Mosti S, et al. Predictors of progression of cognitive decline in Alzheimer's disease: The role of vascular and sociodemographic factors. J Neurol. 2009;256:1288-1295.
5. Sakurai H, Hanyu H, Sato T, Kanetaka H, Shimizu S, Hirao K, et al. Vascular risk factors and progression in Alzheimer's disease. Geriatr Gerontol Int. 2011;11:211-214.
6. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: Two roads converged. Arch Neurol. 2009;66:300-305.
7. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-1145.
8. Kalaria RN. Vascular basis for brain degeneration: Faltering controls and risk factors for dementia. Nutr Rev. 2010;68(Suppl 2):S74-S87.
9. Burgener SC, Buettner L, Coen Buckwalter K, Beattie E, Bossen AL, Fick DM, et al. Evidence supporting nutritional interventions for persons in early stage Alzheimer's disease (AD). J Nutr Health Aging. 2008;12:18-21.
10. Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol. 2009;66:1210-1215.
11. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10:819-828.
12. Gorelick P, Scuteri A, Black S, Decarli C, Greenberg S, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Stroke. 2011;42:2672-2713.
13. Karow DS, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr, Jennings RG, Brewer JB, et al. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology. 2010;256:932-942.
14. Beason-Held LL, Moghekar A, Zonderman AB, Kraut MA, Resnick SM. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke. 2007;38:1766-1773.
15. Jueptner M, Weiller C. Does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. NeuroImage. 1995;2:148-156.
16. Resnick SM, Goldszal AF, Davatzikos C, Golski S, Kraut MA, Metter EJ, et al. One-year age changes in MRI brain volumes in older adults. Cereb Cortex. 2000;10:464-472.
17. Shock NW, Greulich RC, Andres R, Arenberg D, Costa PT Jr, Lakatta E, et al. Normal human aging: The Baltimore longitudinal study of aging. Washington, DC: U.S. Government Printing Office; 1984.
18. Brett M, Anton J, Valabregue R, Poline J. Region of interest analysis using an SPM toolbox. Neuroimage. 2002;16:1140-1141.
19. Davatzikos C, Genc A, Xu D, Resnick SM. Voxel-based morphometry using the RAVENS maps: Methods and validation using simulated longitudinal atrophy. Neuroimage. 2001;14:1361-1369.
20. Shen D, Davatzikos C. Hammer: Hierarchical attribute matching mechanism for elastic registration. IEEE Transactions on Medical Imaging. 2002;21:1421-1439.
21. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
22. Glodzik L, Rusinek H, Brys M, Tsui WH, Switalski R, Mosconi L, et al. Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia. J Cereb Blood Flow Metab. 2011;31:671-679.
23. Kuczynski B, Jagust W, Chui HC, Reed B. An inverse association of cardiovascular risk and frontal lobe glucose metabolism. Neurology. 2009;72:738-743.
24. Carter CS, Botvinick MM, Cohen JD. The contribution of the anterior cingulate cortex to executive processes in cognition. Rev Neurosci. 1999; 10:49-57.
25. Petrides M. The orbitofrontal cortex: Novelty, deviation from expectation, and memory. Ann N Y Acad Sci. 2007;1121:33-53.
26. Ullsperger M, von Cramon DY. Subprocesses of performance monitoring: A dissociation of error processing and response competition revealed by eventrelated fMRI and ERPs. Neuroimage. 2001;14:1387-1401.
27. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr. 1983;7:590-598.
28. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752-758.
29. Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2007;104:18760-18765.
30. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical disrtibution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebral Cortex. 1991;1:103-116.
31. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351-357.
32. Wolk DA, Klunk W. Update on amyloid imaging: From healthy aging to Alzheimer's disease. Curr Neurol Neurosci Rep. 2009;9:345-352.
33. Sojkova J, Zhou Y, Kraut M, Brasic J, Ferrucci L, Wong D, et al. Spatial pattern of longitudinal changes in amyloid deposition in nondemented older adults. J Cereb Blood Flow Metab. 2009;29:S44.
34. Altman R, Rutledge JC. The vascular contribution to Alzheimer's disease. Clin Sci (Lond). 2010;119:407-421.
35. Breteler MM. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci. 2000;903:457-465.
36. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM. Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. Stroke. 2008;39:349-354.
37. Tiehuis AM, van der Graaf Y, Visseren FL, Vincken KL, Biessels GJ, Appelman AP, et al. Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke. 2008; 39:1600-1603.
38. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes: A systematic review. Diabetes Care. 2006;29:2539-2548.
39. Zade D, Beiser A, McGlinchey R, Au R, Seshadri S, Palumbo C, et al. Interactive effects of apolipoprotein E type 4 genotype and cerebrovascular risk on neuropsychological performance and structural brain changes. J Stroke Cerebrovasc Dis. 2010;19:261-268.
40. Chen X, Wen W, Anstey KJ, Sachdev PS. Effects of cerebrovascular risk factors on gray matter volume in adults aged 60-64 years: A voxel-based morphometric study. Psychiatry Res. 2006;147:105-114.
41. Gianaros PJ, Greer PJ, Ryan CM, Jennings JR. Higher blood pressure predicts lower regional grey matter volume: Consequences on short-term information processing. Neuroimage. 2006;31:754-765.
42. Kumar A, Haroon E, Darwin C, Pham D, Ajilore O, Rodriguez G, et al. Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging. 2008;27:14-19.
43. Last D, Alsop DC, Abduljalil AM, Marquis RP, de Bazelaire C, Hu K, et al. Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care. 2007;30:1193-1199.
44. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009;73:674-680.
45. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76:1485-1491.